- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
Patent holdings for IPC class A61K 31/5377
Total number of patents in this class: 13248
10-year publication summary
|
968
|
934
|
912
|
933
|
998
|
1011
|
878
|
1013
|
1144
|
813
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10174 |
251 |
| Bristol-myers Squibb Company | 4757 |
149 |
| Merck Sharp & Dohme LLC | 3734 |
122 |
| Gilead Sciences, Inc. | 2243 |
119 |
| Takeda Pharmaceutical Company Limited | 2698 |
116 |
| Epizyme, Inc. | 360 |
116 |
| Boehringer Ingelheim International GmbH | 4488 |
114 |
| Celgene Corporation | 1408 |
105 |
| Merck Patent GmbH | 5742 |
101 |
| Genentech, Inc. | 4123 |
98 |
| Taisho Pharmaceutical Co., Ltd. | 847 |
90 |
| F. Hoffmann-La Roche AG | 7796 |
87 |
| Shionogi & Co., Ltd. | 885 |
86 |
| Chugai Seiyaku Kabushiki Kaisha | 1424 |
84 |
| Hoffmann-La Roche Inc. | 3832 |
82 |
| Dana-Farber Cancer Institute, Inc. | 2671 |
80 |
| Janssen Pharmaceutica N.V. | 3150 |
76 |
| Bayer Pharma AG | 1009 |
76 |
| The Regents of the University of California | 20868 |
74 |
| Pfizer Inc. | 3414 |
74 |
| Other owners | 11148 |